AU2003226753B2 - Statin therapy for enhancing cognitive maintenance - Google Patents

Statin therapy for enhancing cognitive maintenance Download PDF

Info

Publication number
AU2003226753B2
AU2003226753B2 AU2003226753A AU2003226753A AU2003226753B2 AU 2003226753 B2 AU2003226753 B2 AU 2003226753B2 AU 2003226753 A AU2003226753 A AU 2003226753A AU 2003226753 A AU2003226753 A AU 2003226753A AU 2003226753 B2 AU2003226753 B2 AU 2003226753B2
Authority
AU
Australia
Prior art keywords
statin
galantamine
dementia
amount
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003226753A
Other languages
English (en)
Other versions
AU2003226753A1 (en
Inventor
Royston John Glasspool
Elane M. Gutterman
Sean Lilienfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2003226753A1 publication Critical patent/AU2003226753A1/en
Application granted granted Critical
Publication of AU2003226753B2 publication Critical patent/AU2003226753B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
AU2003226753A 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance Ceased AU2003226753B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
US60/369,285 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (2)

Publication Number Publication Date
AU2003226753A1 AU2003226753A1 (en) 2003-10-13
AU2003226753B2 true AU2003226753B2 (en) 2007-06-28

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003226753A Ceased AU2003226753B2 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Country Status (22)

Country Link
EP (1) EP1492539B1 (da)
JP (1) JP2005525391A (da)
KR (1) KR100986194B1 (da)
CN (1) CN100528164C (da)
AT (1) ATE331523T1 (da)
AU (1) AU2003226753B2 (da)
BR (1) BR0308293A (da)
CA (1) CA2480275C (da)
CY (1) CY1105545T1 (da)
DE (1) DE60306503T2 (da)
DK (1) DK1492539T3 (da)
EA (1) EA013069B1 (da)
ES (1) ES2268393T3 (da)
HK (1) HK1079688A1 (da)
IL (2) IL164317A0 (da)
MX (1) MXPA04009535A (da)
NO (1) NO20044698L (da)
NZ (1) NZ536111A (da)
PL (1) PL211160B1 (da)
PT (1) PT1492539E (da)
UA (1) UA79605C2 (da)
WO (1) WO2003082298A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
AU2005232447A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of Alzheimers disease
WO2005123068A2 (en) * 2004-06-08 2005-12-29 Axonyx, Inc. Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US20160303146A1 (en) * 2013-12-13 2016-10-20 David A. TABACZYNSKI Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fulton & Benfield, Drugs Aging, 1996, 9(1):60-5 *
Jick et al., Lancet, 2001, 357:562 *

Also Published As

Publication number Publication date
NZ536111A (en) 2006-03-31
CA2480275C (en) 2011-08-16
HK1079688A1 (en) 2006-04-13
CY1105545T1 (el) 2010-07-28
WO2003082298A1 (en) 2003-10-09
EP1492539B1 (en) 2006-06-28
JP2005525391A (ja) 2005-08-25
DE60306503T2 (de) 2007-06-21
MXPA04009535A (es) 2005-01-25
PT1492539E (pt) 2006-11-30
PL371551A1 (en) 2005-06-27
KR100986194B1 (ko) 2010-10-07
CN100528164C (zh) 2009-08-19
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
CN1642555A (zh) 2005-07-20
EA200401295A1 (ru) 2005-02-24
KR20040096608A (ko) 2004-11-16
AU2003226753A1 (en) 2003-10-13
CA2480275A1 (en) 2003-10-09
ES2268393T3 (es) 2007-03-16
DK1492539T3 (da) 2006-10-30
ATE331523T1 (de) 2006-07-15
DE60306503D1 (de) 2006-08-10
IL164317A0 (en) 2005-12-18
NO20044698L (no) 2004-10-29
BR0308293A (pt) 2004-12-28
EP1492539A1 (en) 2005-01-05
UA79605C2 (en) 2007-07-10
PL211160B1 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
US11013712B2 (en) Methods of treating insomnia using a combination therapy of low-dose doxepin and zolpidem
US20030060423A1 (en) Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors
US11980617B2 (en) Methods of treating acute depression and/or acute anxiety
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
WO2008085567A1 (en) Methods of using low-dose doxepin for the improvement of sleep
AU780817B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AU2003226753B2 (en) Statin therapy for enhancing cognitive maintenance
US20050222122A1 (en) Statin therapy for enhancing cognitive maintenance
AU2004317129A1 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
EP1663247B1 (en) Use of oxcarbazepine for the improvement of sleep in patients suffering from chronic pain
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
AU2002323467A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
KR20060130689A (ko) 인지 기능의 감퇴를 억제하기 위한 혼합 약제 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired